

A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

NCT06909214

Status	RECRUITING
Phase	Phase 4
Sponsor	argenx
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (6)

- Is at least 18 years when signing the ICF
- Has been diagnosed with gMG of MGFA class II, III, or IV
- Is seropositive for AChR-Ab
- Is treatment-naïve for gMG or has been administered AChEI for the treatment of gMG
- Had onset of generalized MG signs and/or symptoms within 12 months before screening; candidates who also had onset of ocular MG signs and/or symptoms within 24 months before screening may be enrolled in the study
- ... and 1 more (see full listing online)

Exclusion (3)

- gMG diagnosis of MGFA class I or V
- Underwent a thymectomy prior to screening, except thymectomy for treatment of nonmalignant thymoma prior to the gMG diagnosis
- Prior or current use of any of any systemic corticosteroid therapy or nonsteroidal immunosuppressive therapy for the treatment of gMG

Locations (18 total)

University of California, San Diego - Altman Clinical and Translational Research Institute (ACTRI), La Jolla, California, United States
Samir Macwan, M.D., Inc. (S corporation), Rancho Mirage, California, United States
EZR Research, Boca Raton, Florida, United States
... and 15 more locations